RLX Technology (RLX) is drawing fresh investor attention after hedge funds increased their exposure, while recent analyst downgrades highlighted ongoing regulatory and pricing pressures in the e vapor market.

At a share price of US$2.42, RLX has posted a 1 day share price return of 0.83%, a 7 day share price return of 2.11% and a 30 day share price return of 2.98%. The 90 day share price return shows a decline of 3.59%, which contrasts with a modest 1 year total shareholder return of 1.74% and a 3 year total shareholder return of 4.65%. This points to uneven but currently stabilising momentum following a much longer term 5 year total shareholder return decline of 84.13%.

If this mix of hedge fund interest and regulatory risk has you thinking about where capital could go next, consider widening your search with our 19 top founder-led companies.

With RLX trading at US$2.42, sitting below its average analyst price target and with an indicated intrinsic value gap, you have to ask: is this an overlooked value story, or is the market already pricing in future growth?

Most Popular Narrative: 20.5% Undervalued

With RLX Technology's last close at $2.42 versus a narrative fair value of $3.04, the current setup frames a clear valuation gap built on specific growth and margin assumptions.

The ongoing global shift from traditional cigarettes to reduced-risk products, such as e-vapor and oral nicotine, is growing the overall nicotine alternatives market. RLX's leadership and early move into multi-category offerings position it to capture expanding consumer demand, supporting strong long-term revenue growth.

Rising international health consciousness and regulatory efforts against smoking are accelerating consumer adoption of smokeless and electronic delivery systems. RLX's international expansion and compliance-focused portfolio are poised to benefit from increased user base and higher penetration, likely driving revenue and earnings growth through new market access.

Want to see what is really backing that valuation gap? The most followed narrative leans on fast compounding revenue, shifting margins, and a punchy future earnings multiple. Curious which specific forecasts sit under those headlines and how they feed into that fair value number?

Result: Fair Value of $3.04 (UNDERVALUED)

However, this hinges on regulatory conditions and competition; tighter e vapor rules or aggressive global tobacco entrants could quickly challenge those margin and growth assumptions.

Another Angle On Valuation

The narrative fair value suggests RLX looks undervalued, but the P/E tells a more cautious story. At 26.5x earnings, the shares trade well above the global tobacco average of 14.5x and above a fair ratio of 21.6x, even though they sit below the peer average of 36.7x. Is that a sensible premium, or a pricing risk you would want compensated?

Next Steps

If this mix of optimism and caution feels finely balanced, it is worth checking the full picture for yourself and deciding where you stand, starting with 3 key rewards and 1 important warning sign.

Looking for more investment ideas?

If RLX has sharpened your thinking, do not stop here. Broaden your watchlist now so you are not relying on a single story.

• Target potential mispriced opportunities by scanning our 46 high quality undervalued stocks, built to spotlight companies where fundamentals and price appear out of sync.
• Prioritise resilience first by reviewing the 77 resilient stocks with low risk scores, focused on businesses with calmer risk profiles that may suit steadier portfolios.
• Hunt for under the radar potential by checking the screener containing 24 high quality undiscovered gems, highlighting companies that many investors may not yet be watching closely.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.